Literature DB >> 30460615

Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model.

Wojciech K Panek1, Katarzyna C Pituch1, Jason Miska1, Julius W Kim1, Aida Rashidi1, Deepak Kanojia1, Aurora Lopez-Rosas1, Yu Han1, Dou Yu1, Catalina Lee Chang1, J Robert Kane1, Peng Zhang1, Alex Cordero1, Maciej S Lesniak2.   

Abstract

The immunosuppressive microenvironment is one of the major factors promoting the growth of glioblastoma multiforme (GBM). Infiltration of CD4+CD25+Foxp3+ regulatory T cells (Tregs) into the tumor microenvironment plays a significant role in the suppression of the anti-tumor immunity and portends a dismal prognosis for patients. Glioma-mediated secretion of chemo-attractant C-C motif ligand 2 and 22 (CCL2/22) has previously been shown by our group to promote Treg migration in vitro. In this study, we show that a local implantation of platelet-rich fibrin patch (PRF-P) into the brain of GL261 glioma-bearing mice prolonged the survival of affected animals by 42.85% (p = 0.0011). Analysis performed on brain tumor tissue harvested from PRF-P-treated mice revealed a specific decrease in intra-tumoral lymphocytes with a preferential depletion of immunosuppressive Tregs. Importantly, co-culture of GL261 or chemo-attractants (CCL2/22) with PRF-P abrogated Treg migration. Pharmacological blockade of the CCL2/22 interaction with their receptors potentiated the inhibitory effect of PRF-P on Tregs recruitment in culture. Moreover, our findings revealed the soluble CD40 ligand (sCD40L) as a major Treg inhibitory player produced by activated platelets entrapped within the fibrin matrix of the PRF-P. Blockade of sCD40L restored the migratory capacity of Tregs, emphasizing the role of PRF-P in preventing the Treg migration to glioma tissue. Our findings highlight autologous PRF-P as a personalized, Treg-selective suppression platform that can potentially supplement and enhance the efficacy of glioma therapies.

Entities:  

Keywords:  Glioblastoma multiforme; Immunosuppressive microenvironment; Platelet-rich fibrin patch; Regulatory T cells and glioma immune therapies

Mesh:

Year:  2018        PMID: 30460615      PMCID: PMC6527506          DOI: 10.1007/s12035-018-1430-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  22 in total

1.  Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway.

Authors:  Xian-zong Ye; Sen-lin Xu; Yan-hong Xin; Shi-cang Yu; Yi-fang Ping; Lu Chen; Hua-liang Xiao; Bin Wang; Liang Yi; Qing-liang Wang; Xue-feng Jiang; Lang Yang; Peng Zhang; Cheng Qian; You-hong Cui; Xia Zhang; Xiu-wu Bian
Journal:  J Immunol       Date:  2012-06-04       Impact factor: 5.422

2.  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

Authors:  Courtney A Crane; Brian J Ahn; Seunggu J Han; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

3.  Platelets suppress Treg recruitment.

Authors:  Rute Moura; Marc Tjwa
Journal:  Blood       Date:  2010-11-18       Impact factor: 22.113

4.  Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion.

Authors:  R P Phipps; J Kaufman; N Blumberg
Journal:  Lancet       Date:  2001-06-23       Impact factor: 79.321

5.  An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions.

Authors:  Neil Blumberg; Kelly F Gettings; Chantal Turner; Joanna M Heal; Richard P Phipps
Journal:  Transfusion       Date:  2006-10       Impact factor: 3.157

6.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Authors:  Roger Stupp; Pierre-Yves Dietrich; Sandrine Ostermann Kraljevic; Alessia Pica; Ivan Maillard; Phillipe Maeder; Reto Meuli; Robert Janzer; Gianpaolo Pizzolato; Raymond Miralbell; François Porchet; Luca Regli; Nicolas de Tribolet; René O Mirimanoff; Serge Leyvraz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 7.  The platelet as an immune cell-CD40 ligand and transfusion immunomodulation.

Authors:  Neil Blumberg; Sherry L Spinelli; Charles W Francis; Mark B Taubman; Richard P Phipps
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

8.  Levels of plasma sulfatides C18 : 0 and C24 : 1 correlate with disease status in relapsing-remitting multiple sclerosis.

Authors:  Ana L Moyano; Katarzyna Pituch; Guanan Li; Richard van Breemen; Jan E Mansson; Maria I Givogri
Journal:  J Neurochem       Date:  2013-07-09       Impact factor: 5.372

9.  Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.

Authors:  Oliver M Grauer; Roger P M Sutmuller; Wendy van Maren; Joannes F M Jacobs; Erik Bennink; Liza W J Toonen; Stefan Nierkens; Gosse J Adema
Journal:  Int J Cancer       Date:  2008-04-15       Impact factor: 7.396

10.  Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.

Authors:  Justin T Jordan; Wei Sun; S Farzana Hussain; Guillermo DeAngulo; Sujit S Prabhu; Amy B Heimberger
Journal:  Cancer Immunol Immunother       Date:  2007-05-24       Impact factor: 6.968

View more
  3 in total

Review 1.  Thrombin generation and activity in multiple sclerosis.

Authors:  Kelley R Jordan; Ivan Parra-Izquierdo; András Gruber; Joseph J Shatzel; Peter Pham; Larry S Sherman; Owen J T McCarty; Norah G Verbout
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

2.  Responses of canine periodontal ligament cells to bubaline blood derived platelet rich fibrin in vitro.

Authors:  Poranee Banyatworakul; Thanaphum Osathanon; Sujin Chumprasert; Prasit Pavasant; Nopadon Pirarat
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

3.  Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma.

Authors:  Johannes Wach; Stefanos Apallas; Matthias Schneider; Johannes Weller; Patrick Schuss; Hartmut Vatter; Ulrich Herrlinger; Erdem Güresir
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.